FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	$D \subset$	20540	
vvasiiiiluluii.	D.C.	20049	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1(0). 30	ee Instruction 1	U																		
		Reporting Person*					me <mark>and</mark> Tic Therap			Symbol					o of Reportir llicable)	ng Person(s)	o Issuer			
Kulkarni Samarth					[1	Direc	tor	10%	6 Owner			
(Last)	(Fir	st) (I	Middle)		3. Date of Earliest Transaction (Month/Day/Year)								1	Office below	er (give title v)	Oth belo	er (specify ow)			
C/O CRISPR THERAPEUTICS					11/11/2024									C	Chief Exec	ief Executive Officer				
105 WEST FIRST STREET																				
,					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable						
(Street)	.T. 3.6		2127										ine)	Form	filed by One	e Reporting F	erson			
BOSTO	N MA	A 0	2127												•	re than One I				
(City)	(Sta	ate) (2	Zip)											Perso	on					
		Table	I - No	on-Deriva	tive	Secui	rities Acc	quirec	d, Di	sposed of	, or Be	enefic	ially	Own	ed					
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			5. Amount of Securities Beneficially Owned Follo Reported		ties cially d Following	6. Ownershi Form: Direc (D) or Indire (I) (Instr. 4)	of Indirect Beneficial Ownership				
								Code	v	Amount	(A) or (D)	Price		Transa	rted action(s) 3 and 4)		(Instr. 4)			
Common Shares				11/11/2024				S ⁽¹⁾		23,121	D	\$55.4	13(2) 20		3,419	D				
Common Shares			11/11/2	.024			S ⁽¹⁾		6,879	D	\$56.2	7(3)		06,540	D					
Common Shares														85,622		The Kulkarni 2023 GRAT				
		Tal	ble II							osed of, o				Owne	d					
4 Tid 5	•	0 7	04 B			alis, v		_					_		0 N	- 6 40	44 Notono			
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Curity or Exercise (Month/Day/Year) if any		emed 4. Transa Code (n/Day/Year)				6. Date Exerc Expiration D (Month/Day/\)		ate	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		Der Sec	Price of erivative ecurity estr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form: Direct (or Indir (I) (Insti	Beneficial Ownership ect (Instr. 4)				
					Code	v	(A) (D)	Date Exerc	isable	Expiration Date		Amount or Number of Shares								

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2024.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$55.00 to \$55.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$56.00 to \$56.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

/s/ Elizabeth Ryland Waldinger, attorney-in-fact

11/13/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.